Skip to main content
SpringerLink
Log in

Avatrombopag: First Global Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Avatrombopag (Doptelet®) is an orally bioavailable, small molecule thrombopoietin receptor agonist that has been developed by Dova Pharmaceuticals for the treatment of thrombocytopenic disorders. In May 2018 avatrombopag received its first global approval, in the USA, for use in the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. A Marketing Authorization Application for use of avatrombopag in this indication was submitted to the EMA in April 2018. Clinical development of avatrombopag in the treatment of other thrombocytopenic disorders, including immune thrombocytopenic purpura and chemotherapy-induced thrombocytopenia, is ongoing. This article summarizes the milestones in the development of avatrombopag leading to this first approval for the treatment of thrombocytopenia in adult patients with CLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23.

    Article  PubMed  CAS  Google Scholar 

  2. Basciano PA, Bussel JB. Thrombopoietin-receptor agonists. Curr Opin Hematol. 2012;19(5):392–8.

    Article  PubMed  CAS  Google Scholar 

  3. Qureshi K, Patel S, Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. Int J Hepatol. 2016;2016:1802932.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012;367(8):716–24.

    Article  PubMed  CAS  Google Scholar 

  5. US FDA. Doptelet® (avatrombopag) tablets: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf. Accessed 21 Jun 2018.

  6. Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018. https://doi.org/10.1053/j.gastro.2018.05.025.

    Article  PubMed  Google Scholar 

  7. US FDA. FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure [media release]. 2018. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608320.htm. Accessed 21 Jun 2018.

  8. Dova Pharmaceuticals. Dova Pharmaceuticals announces FDA acceptance of the avatrombopag new drug application (NDA) with Priority Review [media release]. 2017. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-acceptance-avatrombopag-new. Accessed 21 Jun 2018.

  9. Dova Pharmaceuticals. Dova Pharmaceuticals reports first quarter 2018 operating and financial results [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-reports-first-quarter-2018-operating-and. Accessed 21 Jun 2018.

  10. US FDA. Orphan drug designations and approvals. 2011. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=325110. Accessed 21 Jun 2018.

  11. Dova Pharmaceuticals. Dova Pharmaceuticals provides update on development strategy for avatrombopag in immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT) [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-provides-update-development-strategy. Accessed 21 Jun 2018.

  12. Eisai Co. Ltd. Eisai completes acquisition of MGI Pharma [media release]. 2008. https://www.eisai.com/news/news200803.html. Accessed 21 Jun 2018.

  13. Eisai Co. Ltd. Eisai completes acquisition of AkaRx, Inc. and continues development of AKR-501 for thrombocytopenia [media release]. 2010. https://www.eisai.com/news/news201001.html. Accessed 21 Jun 2018.

  14. Eisai Co. Ltd. Eisai’s U.S. subsidiary Eisai Inc. enters share purchase agreement concerning AkaRx Inc. in the U.S. [media release]. 2016. https://www.eisai.com/news/news201618.html. Accessed 21 Jun 2018.

  15. Dova Pharmaceuticals. Dova Pharmaceuticals signs exclusive distribution agreement with Fosun Pharma for mainland China and Hong Kong [media release]. 2018. http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-signs-exclusive-distribution-agreement. Accessed 21 Jun 2018.

  16. Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253–9.

    Article  PubMed  CAS  Google Scholar 

  17. Frelinger AL, Koganov ES, Forde EE, et al. Avatrombopag, a novel thrombopoietin receptor agonist, increases platelet counts without increasing platelet activation in patients with thrombocytopenia due to chronic liver disease [abstract]. Blood. 2017;130(Suppl 1):290.

    Google Scholar 

  18. Nomoto M, Pastino G, Rege B, et al. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018;7(2):188–95.

    Article  PubMed  CAS  Google Scholar 

  19. Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Br J Clin Pharmacol. 2018;84(5):952–60.

    Article  PubMed  CAS  Google Scholar 

  20. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–94.

    Article  PubMed  CAS  Google Scholar 

  21. Jurczak W, Chojnowski K, Mayer J, et al. Avatrombopag, a novel oral thrombopoietin receptor agonist, demonstrates superiority to placebo for the treatment of chronic immune thrombocytopenic purpura in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial [abstract]. Blood. 2017;130(Suppl 1):17.

    Google Scholar 

  22. US FDA. Promacta® (eltrombopag) tablets: US prescribing information. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022291s019lbl.pdf. Accessed 21 Jun 2018.

Download references

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Matt Shirley

Authors
  1. Matt Shirley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matt Shirley.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The original article has been corrected.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirley, M. Avatrombopag: First Global Approval. Drugs 78, 1163–1168 (2018). https://doi.org/10.1007/s40265-018-0949-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-0949-8

Search

Navigation